dc.date.accessioned2023-07-18T16:18:55Z
dc.date.accessioned2024-04-24T13:19:38Z
dc.date.available2023-07-18T16:18:55Z
dc.date.available2024-04-24T13:19:38Z
dc.date.created2023-07-18T16:18:55Z
dc.date.issued2023
dc.identifierhttps://hdl.handle.net/20.500.12866/13914
dc.identifierhttps://doi.org/10.1016/j.wnsx.2023.100205
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9231149
dc.description.abstractPoor outcomes of aneurysmal subarachnoid hemorrhage (aSAH) can be the result of the initial catastrophic event or the many acute or delayed neurological complications. Recent evidence suggests that some molecules play a critical role in both events, through some unknown pathways involved. Understanding the role of these molecules in these events could allow to improve diagnostic accuracy, guide management, and prevent long-term disability in aSAH. Here we present the studies on aSAH biomarkers present in current medical literature, highlighting their roles and main results.
dc.languageeng
dc.publisherElsevier
dc.relationWorld neurosurgery X
dc.relation2590-1397
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAneurysmal subarachnoid hemorrhage
dc.subjectSubarachnoid hemorrhage
dc.subjectBiomarkers
dc.subjectNeuroinflammatory markers
dc.subjectAneurysm
dc.titleBiomarkers in aneurysmal subarachnoid hemorrhage: A short review.
dc.typeinfo:eu-repo/semantics/review


Este ítem pertenece a la siguiente institución